SAN FRANCISCO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that members of senior management will participate in the 8th Annual Evercore Healthcare Conference, taking place in Miami, including a fireside chat on Wednesday, December 3, 2025, at 1:20 pm ET. The webcast will be available online at https://investors.omadahealth.com/news-events/events. A replay will also be available at the same link following the event. About Omad ...

Core Insights - QKS Group has recognized Omada as a Technology Leader and Emerging Innovator in the Q4 2025 SPARK Matrix for Identity Governance and Administration (IGA) [1][5] - The SPARK Matrix provides a comprehensive analysis of market dynamics, trends, vendor landscape, and competitive positioning in the IGA sector [1][5] Company Overview - Omada is a global leader in Identity Governance and Administration, offering a cloud-native IGA solution that enhances compliance, reduces risk, and maximizes operational efficiency [3] - Founded in 2000, Omada specializes in innovative identity management solutions tailored for complex hybrid environments [3] Technology and Innovation - Omada's platform integrates cloud-native architecture with near-real-time governance intelligence, utilizing an event-driven architecture and AI assistant Javi to improve compliance and decision-making [2] - The company's secure Cloud Application Gateway and BYOK (Bring Your Own Key) support enhance trust and make it a preferred choice for organizations seeking agility without sacrificing governance integrity [2] Market Positioning - Omada's recognition by QKS Group validates its vision of modern identity governance, which balances agility and control for enterprises navigating complex digital ecosystems [2] - The company aims to deliver IGA solutions that adapt to the rapid pace of change while ensuring compliance with regulatory requirements [2]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ___________________________ (Exact name of registrant as specified in its charter) _________________________ Delaware 45-2355015 (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Comm ...

For the quarter ended September 2025, Omada Health, Inc. (OMDA) reported revenue of $68.03 million, representing no change compared to the same period last year. EPS came in at $0.02, compared to $0 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $61.15 million, representing a surprise of +11.25%. The company delivered an EPS surprise of +120%, with the consensus EPS estimate being -$0.10.While investors closely watch year-over-year changes in headline numbers -- rev ...

Financial Data and Key Metrics Changes - Total members increased by 53% year over year to 831,000, with revenue growing by 49% year over year to $68 million [4][22] - GAAP gross margin reached 66%, while non-GAAP gross margin was at 68%, both showing significant improvement from the previous year [4][23] - The net loss was reduced to $3 million compared to $9 million in Q3 2024, marking a notable improvement in financial performance [4][24] - For the first time, the company achieved a positive adjusted EBITDA of $2 million, compared to a loss of $5 million in Q3 2024 [4][24] Business Line Data and Key Metrics Changes - The GLP-1 CareTrack program has been a significant driver of growth, reflecting strong demand and multi-condition adoption [11][22] - The company reported that 75% of new customers opted for multiple Omada programs, indicating the appeal of its integrated multi-condition platform [12] Market Data and Key Metrics Changes - The company has seen healthy activity in the current selling season, with early sales traction through a large new channel partner, representing an estimated 180,000 individuals [11] - The demand for GLP-1 offerings has been a key factor in the company's growth, with significant interest from employers and health plans [6][22] Company Strategy and Development Direction - The company plans to invest in GLP-1 offerings and AI technologies, aiming to enhance its solutions and widen its competitive moat [9][25] - The strategic focus is on delivering integrated care that combines clinical services with behavioral support, addressing the complexities of medication management [6][16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting the potential for growth in 2026 and beyond, driven by innovations in GLP-1 therapies and AI integration [9][10] - The company aims to achieve sustained profitability while continuing to invest in key areas that can enhance its service offerings [25] Other Important Information - The company published its 30th peer-reviewed manuscript, demonstrating the effectiveness of its programs in reducing medical costs and improving health outcomes [18][19] - The company ended Q3 with cash and cash equivalents of $199 million, down from $223 million in Q2 2025, primarily due to debt repayment [25] Q&A Session Summary Question: Can you discuss the new GLP-1 prescribing initiative? - Management highlighted that the new prescribing capability will be integrated within the Omada Care program, allowing members to fulfill prescriptions at their chosen pharmacy [30][31] Question: What investments are needed to launch this new offering? - Management indicated that investments will be required across engineering, product, sales, and marketing to support the new prescribing functionality [39] Question: How is the selling season progressing? - Management noted that they are seeing strong multi-product penetration and healthy activity in the selling season, with double-digit volume deal growth year over year [40] Question: How does GLP-1 drive growth in the overall portfolio? - Management stated that while GLP-1 CareTrack contributes to growth, the majority of new members still come from non-GLP-1 offerings, reflecting a successful multi-product sales strategy [76]

As of November 6, 2025 Building a Between-Visit Provider Our Mission Bend the curve Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, macroeconomic and industry conditions, and other factors. Because forward-looking statements relate to the future, they are subject to inhere ...

New capability to provide tailored and coordinated care informed by behavioral insightsSAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit health care provider, today announced the planned launch of its prescribing capability. After reporting 53% year-over-year member growth as of the end of Q3, the company is also expanding its offerings. A new option of prescribing and medication management of anti-obesity medications (AOM), including GLP-1s, will ...

Revenue of $68 million, up 49%; 53% Member GrowthSignificant Reduction in Net Loss and First Quarter of Positive Adjusted EBITDAAnnounces New GLP-1 Prescribing Offering SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Omada Health, Inc. (Nasdaq: OMDA), the virtual between-visit healthcare provider, today reported financial results for the third quarter ended September 30, 2025. 2025 Third Quarter Highlights Total members of 831,000, up 53% compared with the third quarter of 2024Revenue of $68 million, up 49 ...

Omada Health Reports Third Quarter 2025 Results Revenue of $68 million, up 49%; 53% Member Growth Significant Reduction in Net Loss and First Quarter of Positive Adjusted EBITDA Announces New GLP-1 Prescribing Offering SAN FRANCISCO - November 6, 2025 - Omada Health, Inc. (Nasdaq: OMDA), the virtual between-visit healthcare provider, today reported financial results for the third quarter ended September 30, 2025. 2025 Third Quarter Highlights "Our third quarter results demonstrate the strength of Omada's mu ...

Virtual care company Omada Health on Thursday said it will start prescribing GLP-1s and other obesity drugs and helping patients manage those medications.Omada plans to expand the offerings under its weight management program as its membership grows to more than 100,000. The announcement comes as digital health companies increase their presence in the blockbuster market for GLP-1s to treat obesity, diabetes and other chronic conditions – a space that could be worth roughly $100 billion by the end of the dec ...